CATX Q3 EPS Increased by Brookline Capital Management

Key Points

• Brookline Capital Management raised its Q3 2025 earnings per share estimate for Perspective Therapeutics from ($0.37) to ($0.36), while anticipating full-year earnings at ($0.88) per share.
• Analysts have mixed views on Perspective Therapeutics, with three analysts rating it as a Strong Buy, while others have set price targets ranging from $8.00 to $16.00.
• The stock of Perspective Therapeutics opened at $3.38 and has experienced a significant price fluctuation, with a 52-week low of $1.60 and a high of $16.55.

Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Equities researchers at Brookline Capital Management upped their Q3 2025 earnings per share estimates for shares of Perspective Therapeutics in a research note issued to investors on Monday, August 18th. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings of ($0.36) per share for the quarter, up from their previous estimate of ($0.37). The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Perspective Therapeutics' Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.33) EPS, Q1 2026 earnings at ($0.44) EPS, Q2 2026 earnings at ($0.45) EPS, Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.57) EPS and FY2026 earnings at ($1.98) EPS.

Other equities research analysts have also recently issued research reports about the company. B. Riley restated a "buy" rating and issued a $12.00 target price (up previously from $9.00) on shares of Perspective Therapeutics in a research note on Monday, June 23rd. Truist Financial cut their target price on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Royal Bank Of Canada raised Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and increased their price target for the company from $15.00 to $16.00 in a research report on Tuesday, June 3rd. Wedbush reissued an "outperform" rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Monday, June 23rd. Finally, Lifesci Capital raised Perspective Therapeutics to a "strong-buy" rating in a research report on Saturday, July 12th. Three research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $12.56.

Perspective Therapeutics Trading Up 2.5%

NYSE CATX traded up $0.09 during trading on Thursday, hitting $3.55. The stock had a trading volume of 257,539 shares, compared to its average volume of 934,553. The company's 50-day moving average price is $3.79 and its two-hundred day moving average price is $2.96. Perspective Therapeutics has a 12 month low of $1.60 and a 12 month high of $16.31.

Institutional Trading of Perspective Therapeutics

Several hedge funds have recently added to or reduced their stakes in CATX. Millennium Management LLC bought a new position in Perspective Therapeutics during the 4th quarter worth $4,132,000. Nuveen LLC bought a new position in Perspective Therapeutics during the 1st quarter worth $2,647,000. Affinity Asset Advisors LLC increased its stake in Perspective Therapeutics by 71.1% during the 1st quarter. Affinity Asset Advisors LLC now owns 2,224,196 shares of the company's stock worth $4,738,000 after acquiring an additional 924,196 shares during the period. Octagon Capital Advisors LP increased its stake in Perspective Therapeutics by 62.1% during the 4th quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company's stock worth $7,352,000 after acquiring an additional 882,528 shares during the period. Finally, Two Sigma Investments LP bought a new position in Perspective Therapeutics during the 4th quarter worth $2,075,000. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.